Clinical Trial: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06385496) titled 'Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)' on April 25.

Brief Summary: This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called mTOR mutations. MLN0128 (TAK-228) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Type: Interventional

Condition: * Advanced Lymphoma

* Advanced Malignant Solid Neoplasm

* Refractory Lymphoma

* Refractory Malignant Solid Neoplasm

* Refractory Multiple Myeloma

Intervention: * Procedur...